VASCADE VASCULAR CLOSURE SYSTEM
Cardiva Medical, Inc. · Decision date Jan 31, 2013
What did the FDA approve?
FDA approved the VASCADE Vascular Closure System under PMA P120016 on January 31, 2013. The approval covers femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a 5F, 6F, or 7F procedural sheath.
The approval also covers reducing time to discharge eligibility, but only for patients who have undergone diagnostic endovascular procedures using a 5F, 6F, or 7F procedural sheath. The statement does not include safety or effectiveness data, and the source fields do not identify any supplement or change to a prior PMA.
FDA approval order statement
APPROVAL FOR THE VASCADE¿ VASCULAR CLOSURE SYSTEM (VCS). THIS DEVICE IS INDICATED FOR FEMORAL ARTERIAL ACCESS SITE CLOSURE WHILE REDUCING TIMES TO HEMOSTASIS AND AMBULATION IN PATIENTS WHO HAVEUNDERGONE DIAGNOSTIC OR INTERVENTIONAL ENDOVASCULAR PROCEDURES USING A 5F, 6F, OR 7F PROCEDURAL SHEATH. THE VASCADE VCS IS ALSO INDICATED TO REDUCE TIME TO DISCHARGE ELIGIBILITY IN PATIENTS WHO HAVE UNDERGONE DIAGNOSTIC ENDOVASCULAR PROCEDURES USING A 5F, 6F, OR 7F PROCEDURAL SHEATH.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 31, 2013
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120016
- Regulatory pathway
- Premarket approval application
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Jan 31, 2013
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P120016 received
Application receipt date recorded by FDA.
P120016 · FDA decision
APPR
P120016/S043 · Related supplement
VASCADE 5F Vascular Closure System
Timeline entries are records held by MedtechLedger for P120016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VASCADE 5F Vascular Closure SystemP120016/S043 | Cardiva Medical, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cardiva Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2900 Lakeside Dr., Suite 160, Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


